Comparison of orlistat treatment and placebo in obese type 2 diabetic patients

Bibliography

• Kumanyika S, Jeffery RW, Morabia A, Obesity prevention: the case for action. Int J Obes Relat Metab Disord 2002;26:425-36
   PubMed Web of Science ®Google Scholar
• Keller U. From obesity to diabetes. Int J Vitam Nutr Res 2006;76:172-7
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Nutrition principles and recommendations in diabetes. Diabetes Care 2004;27(Suppl 1):36-46
   Google Scholar
• American Diabetes Association. Physical activity/exercise and diabetes. Diabetes Care 2004;27(Suppl 1):58-62
   Google Scholar
• Lee M, Aronne LJ. Weight management for type 2 diabetes mellitus: global cardiovascular risk reduction. Am J Cardiol 2007;99:68B-79B
   PubMed Web of Science ®Google Scholar
• Leung WY, Thomas GN, Chan JC, Tomlinson B. Weight management and current options in pharmacotherapy: orlistat and sibutramine. Clin Ther 2003;25:58-80
   PubMed Web of Science ®Google Scholar
• Zhi J, Melia AT, Guerciolini R, Retrospective population-based analysis of the dose-response (fecal fat excretion) relationship of orlistat in normal and obese volunteers. Clin Pharmacol Ther 1994;56:82-5
   PubMed Web of Science ®Google Scholar
• Torgerson JS, Hauptman J, Boldrin MN, Sjostrom L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004;27:155-61
   PubMed Web of Science ®Google Scholar
• Henness S, Perry CM. Orlistat: a review of its use in the management of obesity. Drugs 2006;66:1625-56
   PubMed Web of Science ®Google Scholar
• Curran MP, Scott LJ. Orlistat: a review of its use in the management of patients with obesity. Drugs 2004;64:2845-64
   PubMedGoogle Scholar
• Filippatos TD, Derdemezis CS, Gazi IF, Orlistat-associated adverse effects and drug interactions. A critical review. Drug Saf 2008;31:53-65
   PubMed Web of Science ®Google Scholar
• McDuffie JR, Calis KA, Uwaifo GI, Efficacy of orlistat as an adjunct to behavioural treatment in overweight African American and Caucasian adolescents with obesity-related co-morbid conditions. J Pediatr Endocrinol Metab 2004;17:307-19
   PubMed Web of Science ®Google Scholar
• Ryden L, Standl E, Bartnik M, Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J 2007;28:88-136
   PubMed Web of Science ®Google Scholar
• World Health Organization. Obesity: preventing and managing the global epidemic. Report of WHO consultation on obesity. Geneva: WHO; 1997
   Google Scholar
• Lichtenstein AH, Appel LJ, Brands M, Summary of American Heart Association diet and lifestyle recommendations revision 2006. Arterioscler Thromb Vasc Biol 2006;26:2186-91
   PubMed Web of Science ®Google Scholar
• Borg G. Perceived exertion as an indicator of somatic stress. Scand J Rehabil Med 1970;2:92-8
   PubMedGoogle Scholar
• Misra A, Garg A. Leptin: its receptor and obesity. J Invest Med 1996;44:540-8
   PubMedGoogle Scholar
• Zhang M, Tracey K. The cytokine handbook. 3rd edition. Academic Press, San Diego; 1988
   Google Scholar
• Yamauchi T, Kamon J, Waki H, The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 2001;7:941-6
   PubMed Web of Science ®Google Scholar
• Hida K, Wada J, Eguchi J, Visceral adipose tissue-derived serine protease inhibitor: a unique insulin-sensitizing adipocytokine in obesity. Proc Natl Acad Sci USA 2005;102:10610-5
   PubMed Web of Science ®Google Scholar
• Rifai N, Tracy RP, Ridker PM. Clinical efficacy of an automated high-sensitivity C-reactive protein assay. Clin Chem 1999;45:2136-41
   PubMed Web of Science ®Google Scholar
• Bunn HF, Gabbay KH, Gallop PM. The glycosylation of haemoglobin. Relevance to diabetes mellitus. Science 1978;200:21-7
   PubMed Web of Science ®Google Scholar
• European Diabetes Policy Group. A desktop guide to type 2 diabetes mellitus. Diabet Med 1999;16:716-30
   PubMed Web of Science ®Google Scholar
• Heding LG. Determination of total serum insulin (IRI) in insulin-treated diabetic patients. Diabetologia 1972;8:260-6
   PubMed Web of Science ®Google Scholar
• Matthews DR, Hosker JP, Rudenski AS, Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-9
   PubMed Web of Science ®Google Scholar
• Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care 2004;27:1487-95
   PubMed Web of Science ®Google Scholar
• Klose S, Borner K. Enzymatische bestimmung des gesamtcholesterins mit dem Greiner Selective Analyzer (GSA II). J Clin Chem Clin Biochem 1978;15:121-30
   Google Scholar
• Wahlefeld AW. Triglycerides – determination after enzymatic hydrolysis. In: Bergmeyer HV, editor, Methods of enzymatic analysis. 2nd edition. Verlag Chemie/Academic Press, New York, London; 1974. p. 18-31
   Google Scholar
• Havel RJ, Edr HA, Bragdon JH. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest 1955;34:1345-53
   PubMed Web of Science ®Google Scholar
• Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low density lipoprotein in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502
   PubMed Web of Science ®Google Scholar
• Winer BJ. Statistical principles in experimental design. 2nd edition. McGraw-Hill, New York; 1971
   Google Scholar
• Mancia G, Laurent S, Agabiti-Rosei E, Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens 2009;27:2121-58
   PubMed Web of Science ®Google Scholar
• International Lipid Information Bureau. The ILIB lipid handbook for clinical practice: dyslipidemia and coronary heart disease. 3rd edition. New York; 2003. p. 1-242
   Google Scholar
• Derosa G, Mugellini A, Ciccarelli L, Effects of orlistat, simvastatin, and orlistat + simvastatin in obese patients with hypercholesterolemia: a randomized, open-label trial. Curr Ther Res Clin Exp 2002;63:621-33
   Google Scholar
• Derosa G, Mugellini A, Ciccarelli L, Fogari R. Randomized double-blind, placebo-controlled comparison of the action of orlistat, fluvastatin, or both on anthropometric measurements, blood pressure, and lipid profile in obese patients with hypercholesterolemia prescribed a standardized diet. Clin Ther 2003;25:1107-22
   PubMed Web of Science ®Google Scholar
• Derosa G, Cicero AFG, Murdolo G, Efficacy and safety comparative evaluation of orlistat and sibutramine treatment in hypertensive obese patients. Diabetes Obes Metab 2005;7:47-55
   PubMed Web of Science ®Google Scholar
• Kelley FE, Bray GA, Pi-Sunyer FX, Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes. Diabetes Care 2002;25:1033-41
   PubMed Web of Science ®Google Scholar
• Jacob S, Rabbia M, Meier MK, Hauptman J. Orlistat 120 mg improves glycaemic control in type 2 diabetic patients with or without concurrent weight loss. Diabetes Obes Metab 1999;4:361-71
   Google Scholar
• Hollander PA, Elbein SC, Hirsch IB, Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study. Diabetes Care 1998;21:1288-94
   PubMed Web of Science ®Google Scholar
• Dixon AN, Valsamakis G, Hanif MW, Effect of the orlistat on serum endotoxin lipopolysaccharide and adipocytokines in South Asian individuals with impaired glucose tolerance. Int J Clin Pract 2008;62:1124-9
   PubMedGoogle Scholar
• Filippatos TD, Gazi IF, Liberopoulos EN, The effect of orlistat and fenofibrate, alone or in combination, on small dense LDL and lipoprotein associated phospholipase A2 in obese patients with metabolic syndrome. Atherosclerosis 2007;193:428-37
   PubMed Web of Science ®Google Scholar
• Filippatos TD, Kiortsis DN, Liberopoulos EN, Effect of orlistat, micronised fenofibrate and their combination on metabolic parameters in overweight and obese patients with the metabolic syndrome: the FenOrli study. Curr Med Res Opin 2005;21:1997-2006
   PubMed Web of Science ®Google Scholar
• Nakou ES, Filippatos TD, Georgoula M, The effect of orlistat and ezetimibe, alone or in combination, on serum LDL and small dense LDL cholesterol levels in overweight and obese patients with hypercholesterolaemia. Curr Med Res Opin 2008;24:1919-29
   PubMed Web of Science ®Google Scholar
• Mittendorfer B, Ostlund RF, Patterson BW, Klein S. Orlistat inhibits dietary cholesterol absorption. Obes Res 2001;9:599-604
   PubMedGoogle Scholar
• Cho LW, Kilpatrick ES, Keevil BG, Effect of metformin, orlistat and pioglitazone treatment on mean insulin resistance and its biological variability in polycystic ovary syndrome. Clin Endocrinol 2009;70:233-7
   PubMed Web of Science ®Google Scholar
• Hsieh CJ, Wang PW, Liu RT, Orlistat for obesity: benefits beyond weight loss. Diabetes Res Clin Pract 2005;67:78-83
   PubMed Web of Science ®Google Scholar
• Uysal KT, Wiesbrock SM, Marino MW, Hotamisligil GS. Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function. Nature 1997;389:610-4
   PubMed Web of Science ®Google Scholar
• Hotamisligil GS. The role of TNF-alpha and TNF receptors in obesity and insulin resistance. J Intern Med 1999;245:621-5
   PubMed Web of Science ®Google Scholar
• Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 1993;259:87-91
   PubMed Web of Science ®Google Scholar
• Jackson MB, Ahima RS. Neuroendocrine and metabolic effects of adipocyte-derived hormones. Clin Sci 2006;110:143-52
   PubMedGoogle Scholar
• Berg AH, Combs TP, Scherer PE. ACRP30/adiponectin: an adipokine regulating glucose and lipid metabolism. Trends Endocrinol Metab 2002;13:84-9
   PubMed Web of Science ®Google Scholar
• Bouskila M, Pajvani UB, Scherer PE. Adiponectin: a relevant player in PPARgamma-agonist mediated improvements in hepatic insulin sensitivity? Int J Obes Relat Metab Disord 2005;29(Suppl 1):17-23
   Google Scholar
• Maeda N, Shimomura I, Kishida K, Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat Med 2002;8:731-7
   PubMed Web of Science ®Google Scholar
• Berg AH, Combs TP, Du X, The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat Med 2001;7:947-53
   PubMed Web of Science ®Google Scholar
• Kiortsis DN, Filippatos TD, Elisaf MF. The effects of orlistat on metabolic parameters and other cardiovascular risk factors. Diabetes Metab 2005;31:15-22
   PubMed Web of Science ®Google Scholar
• Harrison SA, Fecht W, Brunt EM, Neuschwander-Tetri BA. Orlistat for overweight subjects with nonalcoholic steatohepatitis: a randomized, prospective trial. Hepatology 2009;49:80-6
   PubMed Web of Science ®Google Scholar
• Flier JS. Obesity wars: molecular progress confronts an expanding epidemic. Cell 2004;116:337-50
   PubMed Web of Science ®Google Scholar
• Zwacka TP, Hornbach V, Torzewski J. C-reactive protein-mediated lipoprotein uptake by macrophages. Circulation 2001;103:1194-7
   PubMed Web of Science ®Google Scholar
• Yesilbursa D, Serdar A, Heper Y, The effect of orlistat-induced weight loss on interleukin-6 and C-reactive protein levels in obese subjects. Acta Cardiol 2005;60:265-9
   PubMed Web of Science ®Google Scholar
• Valsamakis G, McTernan PG, Chetty R, Modest weight loss and reduction in waist circumference after medical treatment are associated with favorable changes in serum adipocytokines. Metabolism 2004;53:430-4
   PubMed Web of Science ®Google Scholar
• Derosa G, Cicero AF, Murdolo G, Comparison of metabolic effects of orlistat and sibutramine treatment in type 2 diabetic obese patients. Diabetes Nutr Metab 2004;17:222-9
   PubMedGoogle Scholar
• Madsen EL, Rissanen A, Bruun JM, Weight loss larger than 10% is needed for general improvement of levels of circulating adiponectin and markers of inflammation in obese subjects: a 3-year weight loss study. Eur J Endocrinol 2008;158:179-87
   PubMed Web of Science ®Google Scholar
• Sundl I, Pail E, Mellitzer K, Effects of orlistat therapy on plasma concentrations of oxygenated and hydrocarbon carotenoids. Lipids 2006;41:113-8
   PubMedGoogle Scholar